External broker reports(aggregated public sources), Wilsons Advisory

Wilsons Advisory

Wilsons has a distinguished history in financial services that spans over 125 years. Today, the group has significant capabilities in private wealth management, corporate finance, research and investment strategy, and institutional sales. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<div><div><div><ul><li>We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals with a revised price target of $1.22/sh.</li><li>We view the upcoming release of Clarity’s Phase I/II PROPELLER trial results for their 64Cu-SAR-bisPSMA in prostate cancer diagnosis as a de-risking event, with clear signals towards a positive outcome.</li><li>The readout represents an important step in Clarity’s development to a) verify the efficacy of their coupled SAR-copper technology; and b) transition the company into ‘pivotal- trial stage’, as Clarity move closer towards unlocking revenue to support longer-term programs. </li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals with a revised price target of $1.22/sh.We view the upcoming release of Clarity’s Phase I/II PROPELLER trial results for their 64Cu-SAR-bisPSMA in prostate cancer diagnosis as a de-risking event, with clear signals towards a positive outcome.The readout represents an important step in Clarity’s development to a) verify the efficacy of their coupled SAR-copper technology; and b) transition the company into ‘pivotal- trial stage’, as Clarity move closer towards unlocking revenue to support longer-term programs. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - PROPELLED to Upgrade